BioShield Starts Process For Countermeasure Acquisition For Four Bioterror Threats
This article was originally published in The Pink Sheet Daily
Executive Summary
Department of Homeland Security has issued material threat determinations for anthrax, smallpox, botulinum toxin and radiological/nuclear devices. Government bioterror countermeasure acquisition process cannot commence unless MTD has been issued for an agent.
You may also be interested in...
HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield
Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.
HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield
Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.
Senate “BioShield II” Hearing On Incentives Slated Tentatively For Oct. 6
The joint Senate HELP-Judiciary hearing will include representatives from small and large companies and feature discussion on greater funding and stronger liability protections than are included in the existing BioShield law.